To hear about similar clinical trials, please enter your email below
Trial Title:
Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
NCT ID:
NCT06080061
Condition:
Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
Hypofractionated accelerated radiation therapy
Description:
Hypofractionated accelerated radiation therapy
Arm group label:
Hypofractionated accelerated radiation therapy (HART)
Summary:
The purpose of this study is to examine the use of hypofractionated accelerated radiation
therapy (HART) to treat locally advanced lung cancer. Depending on the location and size
of the tumor.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Histologically or cytologically documented malignancy of the lung including
non-small cell lung cancer or small cell lung cancer planned for definitive therapy
with fractionated radiation (60-66 Gy) and concurrent systemic therapy
- ECOG performance status of 0-2
- Age > 18 years old
- Ability to understand and the willingness to personally sign the written IRB
approved informed consent document
- Estimated life expectancy of 12 weeks or longer
Exclusion Criteria:
- Contraindication to receiving radiotherapy or systemic therapy as determined by
treating radiation and medical oncologist
- Age < 18 years old
- Tumor directly invading the major pulmonary arteries, aorta, heart or proximal
bronchial tree
- Diagnosis of interstitial pulmonary fibrosis
- Previous radiation therapy to the thorax that would result in overlapping high dose
radiation fields
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Stanford University
Address:
City:
Palo Alto
Zip:
94305
Country:
United States
Status:
Recruiting
Contact:
Last name:
Jillian Skerchak
Phone:
650-721-4072
Email:
jskerch1@stanford.edu
Start date:
October 25, 2023
Completion date:
December 2026
Lead sponsor:
Agency:
Stanford University
Agency class:
Other
Collaborator:
Agency:
LUNGevity Foundation
Agency class:
Other
Source:
Stanford University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06080061
